Boehringer Ingelheim will receive a cash payment of $595 million as part of its collaboration with a Chicago-based pharmaceutical firm on a new drug to treat psoriasis and other immunology disorders. Boehringer Ingelheim announced the deal with AbbVie Pharmaceuticals Monday to collaborate on a biological antibody currently under phase three testing for psoriasis, a chronic skin disease that causes scaling and inflammation.